Literature DB >> 2658375

Therapeutic monitoring of cyclosporine following pediatric bone marrow transplantation: problems with sampling from silicone central venous lines.

C L Leson1, S M Bryson, E E Giesbrecht, E F Saunders.   

Abstract

Blood concentrations are commonly used to guide dosing requirements of cyclosporine, due to large variations in pharmacokinetics both between and within individuals. Bone marrow transplant patients at The Hospital for Sick Children are prescribed intravenous cyclosporine as part of the posttransplant immunosuppression protocol. Sampling for blood concentration measurement is generally done via a single-lumen central venous line (CVL). Cyclosporine concentrations sampled by this route were compared with concentrations in peripheral capillary samples taken concurrently. Results from the CVL blood were substantially higher despite appropriate flushing of the CVL between the end of the infusion and the time of sample collection. This discrepancy disappeared once the patient was converted to oral cyclosporine. We conclude that the sampling error is due to drug adsorbed to the silicone CVL catheters during intravenous administration and displaced during blood sample collection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658375     DOI: 10.1177/106002808902300405

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  3 in total

1.  Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.

Authors:  Alena Y Z Edwards; Jeffrey M Skolnik; Erin Dombrowsky; Dimple Patel; Jeffrey S Barrett
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

2.  Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer.

Authors:  Jeffrey M Skolnik; Alena Y Zhang; Jeffrey S Barrett; Peter C Adamson
Journal:  Ther Drug Monit       Date:  2010-12       Impact factor: 3.681

3.  Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  K B Miller; D P Schenkein; R Comenzo; J K Erban; T Fogaren; C A Hirsch; E Berkman; A Rabson
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.